These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Research progress on molecular pathogenesis of myeloproliferative neoplasms]. Liu L; Xiao ZJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261 [TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [TBL] [Abstract][Full Text] [Related]
7. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563 [TBL] [Abstract][Full Text] [Related]
8. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307 [TBL] [Abstract][Full Text] [Related]
9. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A; Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858 [TBL] [Abstract][Full Text] [Related]
10. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. Deadmond MA; Smith-Gagen JA J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903 [TBL] [Abstract][Full Text] [Related]
14. Familial chronic myeloproliferative disorders: the state of the art. Rumi E Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677 [TBL] [Abstract][Full Text] [Related]
15. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656 [TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Tefferi A Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355 [TBL] [Abstract][Full Text] [Related]
17. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. Gardner JA; Peterson JD; Turner SA; Soares BL; Lancor CR; Dos Santos LL; Kaur P; Ornstein DL; Tsongalis GJ; de Abreu FB Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171 [TBL] [Abstract][Full Text] [Related]
18. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Shallis RM; Zeidan AM; Wang R; Podoltsev NA Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862 [TBL] [Abstract][Full Text] [Related]
19. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562 [TBL] [Abstract][Full Text] [Related]